Healthcare Professional Portal
PI & AE
EMJ ISGE 2026 – Symposium review: insomnia disorder in menopausal transition
Breaking the silence on insomnia in menopause: updated guidelines and new evidence.
This International Society of Gynecological Endocrinology (ISGE) 2026 symposium review examines insomnia disorder during menopausal transition as an independent chronic condition, covering its impact on quality of life and updated therapeutic approaches, including QUVIVIQ®.
Key takeaways:
Insomnia disorder affects approximately 26–57% of women undergoing menopausal transition and is associated with cognitive deficits and increased risk of psychiatric and cardiometabolic disorders.¹⁻⁵
CBT-I remains the recommended first-line therapy; when insufficient, DORAs – such as QUVIVIQ® – carry the highest-grade (A) recommendation for treatment per the 2023 European Insomnia Guidelines.⁶⁷
QUVIVIQ® 50 mg demonstrated sustained improvements in sleep onset, sleep maintenance, and daytime functioning for up to 1 year, with a favorable safety profile across relevant menopausal subgroups.⁸⁻¹⁰
References
1. Flückiger O et al. Int J Environ Res Public Health. 2025;22(10):1502.
2. Ohayon MM. Arch Intern Med. 2006;166(12):1262-8.
3. Kravitz HM et al. Sleep disturbance during the menopausal transition in a multi-ethnic community sample of women. Sleep. 2008;31(7):979-90.
4. Medic G et al. Short- and long-term health consequences of sleep disruption. Nat Sci Sleep. 2017;9:151-61.
5. Baker FC et al. Sleep and sleep disorders in the menopausal transition. Sleep Med Clin. 2018;13(3):443-56.
6. Vgontzas AN, Fernandez-Mendoza J. Insomnia with short sleep duration: nosological, diagnostic, and treatment implications. J Sleep Med Clin. 2013;8(3):309-22.
7. Riemann D et al. The European insomnia guideline: an update on the diagnosis and treatment of insomnia 2023. J Sleep Res. 2023;32(6):e14035.
8. Mignot E et al. Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials. Lancet Neurol. 2022;21(2):125-39.
9. Kunz D et al. Long-term safety and tolerability of daridorexant in patients with insomnia disorder. CNS Drugs. 2023;37(1):93-106.
10. Schaedel Z et al. Efficacy and safety of daridorexant for the treatment of insomnia disorder in women of menopausal transition age: insights from a randomized controlled trial. Maturitas. 2026;206:108821.
Original source: https://www.emjreviews.com/reproductive-health/symposium/breaking-the-silence-insomnia-disorder-during-menopausal-transition-s15226/ (last visited on 06/08/2026)
Abbreviations
CBT-I: Cognitive Behavioral Therapy for Insomnia; DORA: Dual Orexin Receptor Antagonists.
EUC-IDO-00080 | Date of preparation: June 2026
Copyright © 2026 Idorsia Pharmaceuticals Ltd
Other readers liked
EMJ Symposium Review: Updated Insomnia Guidelines and Latest Real-World Evidence Data on Daridorexant
Educational Video: The Mechanism of Chronic Insomnia
2023 Masterclass: Comprehensive Insights into Sleep Medicine – 5-Hour Full Video Recording
Understand the burden of chronic insomnia in your patients with a concise infographic